Meta‐analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019Meta-Analysis Published on 2021-12-062022-10-04 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Adverse reaction Arbidol Chest computed tomography China Cochrane Library Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 cough COVID‐19 database Day Efficacy and safety evaluate incidence indicated Lopinavir/ritonavir meta‐analysis Mortality multicenter network no difference nucleic acid objective patients Randomized Result SARS‐CoV‐2 searched systematic review Treatment two groups VIP was used [DOI] 10.1002/jmv.27481 PMC 바로가기 [Article Type] Meta-Analysis
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopeniaChAdOx1 nCoV-19 백신 유도 면역 혈전성 혈소판 감소증에 대한 통찰력Article Published on 2021-12-022022-09-11 Journal: Blood [Category] SARS, 유전자 메커니즘, 진단, [키워드] abundance activated addition Adverse reaction aggregate Analysis antibody antibody production antigenic AstraZeneca Autoimmune B-cell response Biomarkers cause ChAdOx1 ChAdOx1 nCoV-19 complex complexes component determinant determinants dissemination DNA EDTA elevated ethylenediaminetetraacetic acid HEK293 heparin heparin-induced thrombocytopenia immune immune responses immunohistochemistry insight mechanism mice Microscopy Mouse models NET NETs neutrophil Neutrophil extracellular trap Neutrophil extracellular traps Neutrophils Pathogenesis pathologic Patient patients PF4 Platelet platelet factor 4 platelet surface Platelets polyphosphate procoagulant proinflammatory Protein proteomics reaction resulting SARS-CoV-2 serum stimulate stimulated Support thrombocytopenia thromboembolic thrombosis thrombotic Thrombotic thrombocytopenia Trigger Vaccine vascular leakage virus [DOI] 10.1182/blood.2021013231 PMC 바로가기 [Article Type] Article
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial건강한 소아 및 청소년을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 이중 맹검, 무작위, 대조, 1/2상 임상 시험Clinical Trial Published on 2021-12-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI Adverse reaction age All participants aluminum Antibody Response Antibody titre assigned Beijing block Block randomisation center children China Chinese clinical trial Control CoronaVac COVID-19 pandemic COVID-19 vaccine detectable development dose dose-escalation double-blind Endpoint enrolled geometric mean titre groups healthy children Humoral response hydroxide inactivated individual Infection injection injection site Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate MOST neutralising antibody occurred Pain participant Participants per-protocol population phase 1 trial Pneumonia prevention primary immunogenicity Program randomised Randomly receive Registered reported Safe Safety safety population safety profile SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Event Seroconversion seroconversion rate severity significant difference Support technology three group Tolerability vaccination Vaccine were excluded [DOI] 10.1016/S1473-3099(21)00319-4 PMC 바로가기 [Article Type] Clinical Trial
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial5 개의 면역 저하 환자 및 전향 적 개방형 임상 시험에서 건강한 대조군에서 SARS-COV-2에 대한 mRNA BNT162B2 백신의 안전성 및 효능Research paper Published on 2021-11-302022-08-13 Journal: EBioMedicine [Category] MERS, SARS, 임상, [키워드] Adverse adverse events Adverse reaction Allogeneic allogeneic hematopoietic stem cell transplantation Antibody titre antibody titres BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination CAR T, Chimeric antigen receptor T CAR-T Cell Cell therapy certain immunocompromised patient groups chronic lymphocytic leukemia clinical trial clinical trials CLL CLL, Chronic lymphocytic leukemia Control controls Council COVID-19, Coronavirus disease 2019 disorder Efficacy event excluded finding FIVE five group foundation funding generally mild group healthy control healthy controls Hematopoietic stem cell highlight HIV HIV, Human immunodeficiency virus HSCT, Allogeneic hematopoietic stem cell transplantation Human immunodeficiency virus human stem-cell transplantation Ibrutinib Immunity Immunocompromised Immunocompromised patient immunocompromised patient group Immunocompromised patients immunodeficiency disorder immunodeficiency disorders IMPROVE Infection ITT, Intention to treat Knut leukemia Lymphocytic leukemia mPP, Modified per protocol mRNA BNT162b2 vaccine mRNA vaccination mycophenolate mycophenolate mofetil occurred of BNT162b2 Open-label organ transplantation organization organizations Patient patient group patient groups PID, Primary immunodeficiency disorders PP, Per protocol primary endpoint Primary Immunodeficiency Prospective clinical trial Rate Region Safe Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 second dose secondary endpoint Secondary endpoints selected serious adverse reaction Seroconversion seroconversion rate seroconverted solid organ solid organ transplantation SOT SOT, Solid organ transplantation stem cell subgroups subject Swedish T cell therapy Treatment vaccination against COVID-19 vaccine dose virus infection [DOI] 10.1016/j.ebiom.2021.103705 PMC 바로가기 [Article Type] Research paper
Cutaneous reactions to COVID‐19 vaccine at the dermatology primary careShort Report Published on 2021-11-272022-10-30 Journal: Immunity, Inflammation and Disease [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] Abstract Adverse reaction Adverse reactions arising Awareness bullous Care Coronavirus disease 2019 coronavirus vaccine COVID‐19 COVID‐19 skin COVID‐19 urticaria COVID‐19 vaccination reaction COVID‐19 vaccine rash cutaneous reaction Dermatology Diseases examined Future groups help Hospitalization immune responses incidence Mild moderate occurred Patient patients primary care promote raised rashe reaction Reactions recognize reduce reported required Result treat vaccination Vaccine vaccine allergy vaccine dose [DOI] 10.1002/iid3.568 PMC 바로가기 [Article Type] Short Report
Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions의료 종사자의 ChAdOx1 nCov-19(AZD1222) 백신 2차 접종 후 Anti-SARS-CoV-2 스파이크 단백질 RBD 항체 수준: 연령, 성별, 비만 및 이상 반응과의 연관성 부족Observational Study Published on 2021-11-252022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 임상, 진단, [키워드] addition Adenovirus adenovirus vector vaccines Adverse Adverse reaction age All participant anti-SARS-CoV-2 Anti-SARS-CoV-2 S antibody Antibody Response ARs asked association AZD1222 BMI body mass index ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Complete Concentration conducted COVID-19 demographics dose enrolled Factor group Hanyang University healthcare worker Immune status injection Level Linear regression mRNA COVID-19 vaccines multivariable obesity participant prospective observational study Protein RBD reaction receive Receptor binding domain response second severity Sex spike stratified subject vaccination Vaccine was measured while [DOI] 10.3389/fimmu.2021.779212 PMC 바로가기 [Article Type] Observational Study
Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatmentReview Published on 2021-11-182022-10-31 Journal: The Egyptian Heart Journal [Category] COVID-19, [키워드] addition administration Adverse reaction Arrhytmia Cardiac arrhythmia cardiac arrhythmias cardiac damage cardiac electrophysiology Cardiac risk cardiovascular COVID-19 death drug interaction forms increased risk medication Pandemia Patient pharmacologic agent pharmacological agent reduce risk severe COVID-19 Severe COVID-19 Infection syndrome Therapeutic treatment treat Treatment Virology [DOI] 10.1186/s43044-021-00228-8 PMC 바로가기 [Article Type] Review
Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal DevelopmentReview Published on 2021-11-182022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Adverse reaction Affect approach caused clinical trials component contribute coronavirus COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine determine development effort fatigue fetal fetal development Fever headache Impact include injection site erythema Maternal Mortality MOST mRNA COVID-19 vaccine Neonatal neonatal development offspring outcome Pain post-hoc Potential pregnant women prenatal reaction required risk SARS-CoV-2 the SARS-CoV-2 vaccination Vaccine Vaccines Viral vector [DOI] 10.3390/vaccines9111351 PMC 바로가기 [Article Type] Review
Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study의료 종사자의 1차 및 2차 ChAdOx1 nCoV-19 백신 접종 전후 5건의 SARS-CoV-2 항체 분석 결과 비교: 전향적 다기관 연구Multicenter Study Published on 2021-11-182022-09-12 Journal: Journal of Clinical Microbiology [Category] MERS, SARS, 진단, [키워드] Abbott acute respiratory syndrome Adverse reaction antibody Antibody titer applied assay assays AstraZeneca Blood ChAdOx1 nCoV-19 changes in Characteristics contributing to coronavirus Efficacy evaluated first dose first vaccination FIVE Genscript IgG immunoassays multicenter study neutralizing antibody participant positive rate Prospective questionnaire reduced Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 pandemic SD Biosensor second second dose second vaccination serological serum sample severity Siemens Symptoms titer vaccination Vaccine Virus neutralization [DOI] 10.1128/JCM.01788-21 PMC 바로가기 [Article Type] Multicenter Study
Cutaneous Adverse Reactions Associated with SARS-CoV-2 VaccinesReview Published on 2021-11-162022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] addition Adverse adverse effects Adverse reaction Adverse reactions affecting atopic dermatitis Autoimmune booster dose bullous Case report case sery Clinical sign collected concerning conditions COVID-19 Cutaneous cutaneous adverse reaction eczematous English language Exanthema generally mild identify Infection injection lesions management manifestation Manifestations mechanisms moderate Morphological outcome Patient reaction Reactions receiving reported Safety SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Symptom the vaccine therapeutic Vaccinations Vaccines variety Vascular [DOI] 10.3390/jcm10225344 PMC 바로가기 [Article Type] Review